Epstein–Barr virus antibody level and gastric cancer risk in Korea: a nested case–control study

Kim, Yonggyun; Shin, Aesun; Gwack, Jin; Ko, K-P; Kim, Chang Sung; Sk, Park; Hong, Yongtaek; Kang, Daehee; Yoo, Keun-Young

doi:10.1038/sj.bjc.6605146

Cited by 21 publications

(26 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In NPC, clearly aberrant IgG diversity patterns are observed in virtually all cases, which is not the case in BL, HD nor in EBV-associated gastric cancer (data not shown; Kim et al 2009). This aberrant IgG response was well known from IFT-based studies, but molecular details and diversity were revealed only recently.…”

Section: Molecular Details Of Anti-ebv Antibody Responses During and mentioning

confidence: 88%

“…This distinct triggering of IgG and IgA (Meij et al 1999;Fachiroh et al 2004;de Sanjosé et al 2007) responses in NPC may relate to aetiological and pathogenic features in NPC currently not well understood, and has relevance for understanding EBV behaviour in vivo in mucosal and submucosal layers in the oropharyngeal (nasal)-associated lymphoid tissue (NALT). The fact that such aberrant anti-EBV antibody responses are not observed in EBV-associated gastric carcinoma (GC, Kim et al 2009) supports the different (late) role of EBV infection in the pathogenesis of this malignancy, distinct from NPC (zur Hausen et al 2004). In NPC, early-stage-enhanced EBV lytic replication in nasopharyngeal epithelia, possibly caused by food components such as nitrosamines and butyrates, is considered to play a pathogenic role which is reflected in early-onset aberrant antibody responses to EBV lytic genes (Ji et al 2007).…”

Section: Molecular Details Of Anti-ebv Antibody Responses During and mentioning

confidence: 91%

See 1 more Smart Citation

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Middeldorp

2015

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is widely distributed in the world and associated with a still increasing number of acute, chronic, malignant and autoimmune disease syndromes. Humoral immune responses to EBV have been studied for diagnostic, pathogenic and protective (vaccine) purposes. These studies use a range of methodologies, from cell-based immunofluorescence testing to antibody-diversity analysis using immunoblot and epitope analysis using recombinant or synthetic peptide-scanning. First, the individual EBV antigen complexes (VCA , MA, EA(D), EA(R) and EBNA) are defined at cellular and molecular levels, providing a historic overview. The characteristic antibody responses to these complexes in health and disease are described, and differences are highlighted by clinical examples. Options for EBV vaccination are briefly addressed. For a selected number of immunodominant proteins, in particular EBNA1, the interaction with human antibodies is further detailed at the epitope level, revealing interesting insights for structure, function and immunological aspects, not considered previously. Humoral immune responses against EBV-encoded tumour antigens LMP1, LMP2 and BARF1 are addressed, which provide novel options for targeted immunotherapy. Finally, some considerations on EBV-linked autoimmune diseases are given, and mechanisms of antigen mimicry are briefly discussed. Further analysis of humoral immune responses against EBV in health and disease in carefully selected patient cohorts will open new options for understanding pathogenesis of individual EBV-linked diseases and developing targeted diagnostic and therapeutic approaches.

show abstract

Section: Molecular Details Of Anti-ebv Antibody Responses During and mentioning

confidence: 88%

Section: Molecular Details Of Anti-ebv Antibody Responses During and mentioning

confidence: 91%

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Middeldorp

2015

Current Topics in Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Second, in 2007, American scholars detected VCA‐IgA, EA‐D IgA, VCA IgG, EA‐D IgG, EA‐R IgG, and EBNA in 185 GC subjects and 200 controls from an area in China where GC is common, and no significance difference was observed between participant groups . Third, in 2009, Korean scholars detected VCA IgG, VCA‐IgA, EBNA‐IgG, and EA‐IgG in 100 GC subjects and 200 controls from a cohort study involving 14440 subjects, and no associations were found between those parameters and GC risk . Fourth, in 2016, the latest report from Africa suggested that the positive rate of EBNA‐1 and EA was associated with GC risk in 51 GC subjects and 96 controls of the Zambia population in Africa .…”

Section: Discussionmentioning

confidence: 99%

“…20 Third, in 2009, Korean scholars detected VCA IgG, VCA-IgA, EBNA-IgG, and EA-IgG in 100 GC subjects and 200 controls from a cohort study involving 14440 subjects, and no associations were found between those parameters and GC risk. 21 Fourth, in 2016, the latest report from Africa suggested that the positive rate of EBNA-1 and EA was associated with GC risk in 51 GC subjects and 96 controls of the Zambia population in Africa. 22 In our study, serum EBV-VCA IgG was detected in 1790 pathologically confirmed Northern Chinese patients with GC and precancerous diseases using ELISA.…”

Section: Discussionmentioning

confidence: 99%

“…17,18 However, few studies have focused on the relationship between EBV serology and GC risk. [19][20][21][22] No investigation has referred to an association between either EBV serology and GC prognosis or EBV and serum gastric function indicators such as pepsinogen I (PGI), pepsinogen II (PGII), pepsinogen I/II (PGI/II), and gastrin-17 (G-17), which could reflect the functional status of gastric mucosa and were thus recognized as indicators for the early detection of GC. 23 In addition, it remains unclear whether the EBV serologic assay has the potential to be a biomarker for GC prediction and prognosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of serum EBV‐VCA IgG detection in assessing gastric cancer risk and prognosis in Northern Chinese population

Wang

Ding

et al. 2018

Cancer Medicine

View full text Add to dashboard Cite

The study aimed to investigate the role of serum EBV‐VCA IgG in assessing gastric cancer (GC) risk and prognosis. A total of 1790 Northern Chinese participants with pathologically confirmed disease underwent EBV‐VCA IgG serologic testing using enzyme‐linked immunosorbent assay (ELISA), including 821 controls, 410 atrophic gastritis (AG) patients, and 559 GC patients. We found that positive EBV‐VCA IgG was significantly associated with GC and its precursor, conferring a 1.55‐ and 1.36‐fold increased risk of GC and AG, respectively (P = 0.001, 95% CI = 1.21‐1.99; P = 0.011, 95% CI = 1.07‐1.72, respectively). The risk effects were more remarkable in younger, female, and Helicobacter pylori‐negative individuals than in older, male, and H. pylori‐positive individuals. EBV‐VCA IgG‐positive subjects had a lower PGI/II ratio than EBV‐VCA IgG‐negative subjects (median 8.0 vs 8.8, P = 0.001), especially those in the H. pylori‐positive (median 6.1 vs 6.8, P = 0.027) and GC subgroups (median 6.4 vs 7.9, P = 0.020). In the intestinal GC subgroup, the survival of EBV‐VCA IgG‐positive patients was worse than that of EBV‐VCA IgG‐negative patients (P = 0.041, HR = 2.45, 95% CI = 1.04‐5.78). Our study suggests that EBV‐VCA IgG seropositivity has potential in predicting the risk of GC and its precursor as well as the prognosis of histologically classified GC.

show abstract

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Xie

Zhong

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) infection is prevalent in global population and associated with multiple malignancies and autoimmune diseases. During the infection, EBV-harbored or infected cell-expressing antigen could elicit a variety of antibodies with significant role in viral host response and pathogenesis. These antibodies have been extensively evaluated and found to be valuable in predicting disease diagnosis and prognosis, exploring disease mechanisms, and developing antiviral agents. In this review, we discuss the versatile roles of EBV antibodies as important biomarkers for EBV-related diseases, potential driving factors of autoimmunity, and promising therapeutic agents for viral infection and pathogenesis.

show abstract

Epstein–Barr virus antibody level and gastric cancer risk in Korea: a nested case–control study

Cited by 21 publications

References 18 publications

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Epstein-Barr Virus-Specific Humoral Immune Responses in Health and Disease

Role of serum EBV‐VCA IgG detection in assessing gastric cancer risk and prognosis in Northern Chinese population

Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy

Contact Info

Product

Resources

About